Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04071366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04071366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2020
Completion date
August 22, 2023
Enrollment
112 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome